| Autor: |
Marinari S; SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy., De Iuliis V; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Dadorante V; Department of Medical, Oral and Biotechnological Sciences, University of Chieti., Colella S; SS Annunziata University Hospital, Unit of Pneumology, Chieti, Italy., Marino A; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Nunziata A; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Flati V; Department of Biotechnological and Applied Clinical Sciences, University of LAquila, Italy., Caruso M; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Pennelli A; Department of Medical, Oral and Biotechnological Sciences, University of Chieti., De Benedetto F; AIMAR (Interdisciplinary Association for the study of Respiratory Diseases), Arona (NO), Italy., Matera S; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Capodifoglio S; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Martinotti S; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Caputi S; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy., Toniato E; Department of Medical, Oral and Biotechnological Sciences, University of Chieti, Italy. |
| Abstrakt: |
Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease of unknown etiology and pathogenic mechanisms. From an etiopathogenic point of view, alveolar macrophages play a key role in accumulation of fibroblasts and deposition of collagen and extracellular matrix by releasing specific cytokines and inflammatory mediators. IPF seems to be also associated with circulating fibrocytes, which might be involved with an abnormal pulmonary vascular repair and remodeling. Based on its hypothesized pathologic mechanisms, anti-inflammatory, anti-fibrotic and immunosuppressive therapies are often used. For these reasons, Interferon-g (IFN-g) has been used to exploit its activity on macrophages and fibroblasts. The aim of this study was to investigate the response to corticosteroids and/or IFN-g 1b treatments based on pulmonary function tests and on inflammatory cytokine patterns of expression on bronchoalveolar lavage (BAL), at baseline and during and after the therapies. Unlike previous studies, we analyzed a period of therapy longer than 1 year. Our results demonstrated the effectiveness of IFN-γ in a group of IPF patients in whom the treatment was prolonged for over a year. These data suggest a positive role of IFN-γ; treatment in patients in the initial stage of the disease. |
